Skip to content
Subscriber Only
Markets

Sinovac Says It’s Yet to Get Efficacy Data on Covid Vaccine

  • Company refutes Indonesia partner’s statement on efficacy rate
  • Efficacy data from trials not ready yet: Sinovac spokesperson
Vials of Sinovac Biotech Ltd.'s CoronaVac SARS-CoV-2 vaccine.

Vials of Sinovac Biotech Ltd.'s CoronaVac SARS-CoV-2 vaccine.

Photographer: Nicolas Bock/Bloomberg
By
Bloomberg News
Updated on

Chinese vaccine maker Sinovac Biotech Ltd.’s coronavirus shot created antibodies among 97% of those administered with it in a final stage trial in Indonesia but its efficacy has yet to be determined, a company spokesperson said Tuesday.

The clarification came after Sinovac’s Indonesian partner, PT Bio Farma, said that the vaccine had proven 97% effective in early clinical trials there. When asked about Sinovac’s response, Bio Farma refrained from agreeing and instead said the final efficacy rate will only be concluded in January.